Korro Bio Accelerates RNA Editing Platform into Clinic with First-in-Human Trial for Hyperammonemia and Designation of AATD Candidate

August 17, 2026

GlobeNewswire (via Korro Bio, Inc.) USA

Overview

Korro Bio has announced plans to initiate first-in-human clinical trials for its hyperammonemia treatment candidate, KRRO-121, in late 2026. Concurrently, the company designated KRRO-111 as a potential ‘best-in-class’ candidate for Alpha-1 Antitrypsin Deficiency (AATD), leveraging a subcutaneously administrable GalNAc-conjugated oligonucleotide. These milestones signify Korro Bio’s successful translation of its innovative RNA editing technology into advanced therapeutic candidates for critical unmet needs in rare diseases.

In Depth

Background

RNA editing represents a significant paradigm shift in treating genetic and other diseases by offering a reversible approach to modify genetic information at the RNA level, rather than directly altering DNA. This technology presents distinct advantages, including a potentially lower risk of off-target effects compared to traditional gene therapies. Korro Bio is a pioneering company in leveraging ADAR (Adenosine Deaminase Acting on RNA) mediated RNA editing technology to develop a pipeline of therapeutics targeting multiple rare diseases. Both hyperammonemia and Alpha-1 Antitrypsin Deficiency (AATD) represent conditions with high unmet medical needs, where existing treatment options are either limited in efficacy or impose significant burdens on patients.

Key Findings

Korro Bio, Inc. recently announced its financial results for Q2 2026 and provided key corporate updates, revealing plans to initiate the first-in-human (FIH) clinical trial for KRRO-121, a potential first-in-class treatment for hyperammonemia, in late 2026. Additionally, the company designated KRRO-111 as a therapeutic candidate for Alpha-1 Antitrypsin Deficiency (AATD), emphasizing its ‘best-in-class’ potential as a subcutaneously administrable GalNAc-conjugated oligonucleotide.

Technology and Clinical Details

Korro Bio’s proprietary platform utilizes ADAR-mediated RNA editing enzymes to specifically modify disease-causing RNA sequences, thereby producing therapeutic effects. This unique approach allows for the correction of gene expression without making permanent changes to the genome. KRRO-121 is designed to address hyperammonemia, a severe metabolic disorder resulting from liver dysfunction or urea cycle defects, which can lead to profound brain dysfunction and be fatal. KRRO-121 aims to normalize blood ammonia levels by precisely regulating the activity of ammonia-metabolizing enzymes at the RNA level. The upcoming FIH trial will be a critical step in evaluating the safety and preliminary efficacy of this novel modality.

Concurrently, KRRO-111 targets Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder characterized by a deficiency of the protease inhibitor alpha-1 antitrypsin (AAT) protein, leading to severe damage in the lungs and liver. KRRO-111 is engineered to restore the production of functional AAT protein through specific RNA editing. A key design feature of KRRO-111 is its formulation as a GalNAc (N-acetylgalactosamine)-conjugated oligonucleotide, enabling specific delivery to the liver and convenient subcutaneous administration. This targeted delivery and simplified administration method could significantly enhance patient convenience compared to current AATD treatments that often require multiple weekly intravenous infusions, positioning KRRO-111 as a potentially ‘best-in-class’ therapy.

Future Outlook

The initiation of the KRRO-121 FIH clinical trial and the designation of KRRO-111 as a candidate drug underscore Korro Bio’s steady progress in translating its RNA editing technology into clinical applications. The success of these programs would not only validate the value of the company’s platform technology but also provide momentum for further pipeline development. The strategic use of GalNAc for targeted delivery is particularly significant, as it enhances the safety and efficacy profile of RNA therapeutics and holds promise for applications in other disease areas. Favorable clinical trial results could offer new hope to patients suffering from hyperammonemia and AATD, marking a pivotal step towards establishing RNA editing as a leading therapeutic modality.

Source: https://ir.korrobio.com/news-releases/news-release-details/korro-reports-second-quarter-2026-financial-results-and-provides

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.